An observational study in Age-related Hearing Loss, sponsored by Chinese PLA General Hospital. Not yet recruiting. Open to participants aged 60 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-29.
Sponsored by Chinese PLA General Hospital · Observational
This study aims to develop a predictive model for age-related hearing loss (ARHL) based on multi-source risk factors and artificial intelligence techniques. A retrospective analysis will be conducted on 1,000 cases with 15-year longitudinal clinical data, including audiological assessments and noise exposure history. Machine learning algorithms will be employed to construct a predictive model for hearing loss progression. Additionally, a prospective cohort of 100 community-dwelling elderly individuals will be enrolled. Blood samples will be collected for low-abundance targeted proteomics analysis to screen for biomarkers associated with cognitive impairment. This study will establish an early risk identification tool for ARHL and propose strategies for the screening and prevention of dementia in individuals with hearing impairment, thereby providing evidence-based support for early intervention in auditory and cognitive health in the elderly.
66 studies on the registry are indexed under Presbycusis; 21 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 123 across 20 observational studies indexed under Presbycusis.
Browse Presbycusis studies →Chinese PLA General Hospital is the lead sponsor of 570 studies on the registry; 207 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study enrolls community-dwelling adults aged ≥60 years from multiple Chinese centers. Inclusion: occupational noise exposure, longitudinal pure-tone audiometry, complete clinical data. Exclusion: non-age/noise hearing loss (e.g., otitis media, otosclerosis, Meniere's disease), missing data >20%, severe mental/cognitive impairment.
The prospective cohort (n=100) recruited from community health centers in North and East China. Inclusion: permanent local residents (≥9 months/year), able to complete assessments, WHO ARHL criteria (PTA≥25 dB HL), written consent. Exclusion: severe psychiatric disorders, major organ failure (NYHA III-IV, eGFR\<30), life expectancy \<3 years, non-ARHL loss, diagnosed dementia, Parkinson's, stroke with severe sequelae, or other unsuitable conditions.
Prospective participants followed at baseline, 12 months. Among them, 50 ARHL with cognitive impairment (MoCA\<26) and 50 with ARHL+normal cognition (MoCA≥26) receive proteomics analysis for biomarker discovery
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Older adults with bilaterally symmetric hearing and no middle ear abnormalities
Other: Not applicable- observational study
Not applicable-observational study
AUC of ARHL machine learning model and cognitive-related protein biomarkers
To evaluate the discriminative performance (area under the receiver operating characteristic curve, AUC) of a machine learning-based predictive model for age-related hearing loss (ARHL) integrating multidimensional risk factors, and to identify serum protein biomarkers associated with cognitive impairment in ARHL patients. Based on a retrospective training cohort of 1,000 participants with 15-year longitudinal data and a prospective external validation cohort of 100 community-dwelling older adults aged 60 years and above, this primary outcome will assess the predictive accuracy (target AUC ≥0.8) of the optimal model (e.g., random forest, XGBoost, or neural network) using standardized pure-tone audiometry, and will determine the diagnostic performance (target AUC ≥0.75) of candidate protein biomarkers for cognitive decline (MoCA \<26) through low-abundance targeted proteomics (pSILAC-HPLC-MS/MS). Repeated cognitive assessments (MoCA, MMSE, CDR) at baseline, 12 months will
Time frame: Baseline and 12 months
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese PLA General Hospital →